ALNOV:EPA
Novacyt SA
€0.45
arrow_downward
-0.22%(-0.00100) 1D
Nov 16, 10:16:49 AM GMT+1 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ALNOV...
Open
€0.45
High
€0.45
Low
€0.44
Mkt. cap
32.66M
Avg. vol.
160.94K
Volume
352.10K
52-wk high
€1.04
52-wk low
€0.29
EPS
-€0.38
Shares outstanding
72.59M
No. of employees
228
Open
€0.45
High
€0.45
Low
€0.44
Mkt. cap
32.66M
Avg. vol.
160.94K
Volume
352.10K
52-wk high
€1.04
52-wk low
€0.29
EPS
-€0.38
Shares outstanding
72.59M
No. of employees
228
News stories
From web sources and news partners
Investing.com
·
1 hour ago
Morgan Stanley raises S&P 500 target on earnings growth, lower oil and AI adoption
MarketWatch
·
49 minutes ago
Stock Market Today: Dow, S&P 500 and Nasdaq are set to fall as investors await Nvidia results and Anthropic's IPO this week: live updates
The Motley Fool
·
2 hours ago
The S&P 500 Looks Cheaper Than It Has in Over 3 Years, but There’s a Catch
Billionaires.Africa
·
56 minutes ago
American billionaire Elon Musk's SpaceX eyes S&P 500 entry through Tesla merger
Profile
Novacyt Group is an Anglo-French biotechnology group focused on clinical diagnostics, with offices in Camberley, Surrey, United Kingdom and Vélizy-Villacoublay, France. The company produces in vitro and molecular diagnostic tests, supplying assays and reagents worldwide. Its business units include Primerdesign, Microgen Bioproducts and Lab21 Healthcare.
In January 2020 the company announced that its molecular diagnostics division, Primerdesign, had launched a molecular test for the 2019 strain of SARSr-CoV. The test was approved as eligible for procurement under the World Health Organization's Emergency Use Listing process in April 2020, meaning that the test could be supplied by the United Nations and other procurement agencies supporting the COVID-19 response. In the same month Novacyt announced a collaboration with AstraZeneca, GlaxoSmithKline and the University of Cambridge to support the UK in its COVID-19 national screening programme at a new testing laboratory at the university's Anne McLaren laboratory. Wikipedia
About Novacyt SA
CEODavid Allmond
Employees228
FoundedJul 3, 2006
Headquarters-
SectorHealth Care
IndustryBiotechnology
Websitenovacyt.com